Difference between revisions of "Columbia Technology Ventures"

From WikiCU
Jump to: navigation, search
 
(28 intermediate revisions by 5 users not shown)
Line 1: Line 1:
−
'''Science and Technology Ventures''' is responsible for managing the transition of Columbia's intellectual property (patents, copyrights, trademarks) from academia to industry.  STV works closely with Columbia's faculty to bridge their work with the corporate world, entrepreneurs and investors.  Since Columbia University is a non-profit and a teaching and research institution, a great many fantastic ideas and inventions are produced on a regular basis but the University can not as part of its mission bring this innovation to the outside world directly.  Instead, STV partners with a commercial partner to adapt University technology for the benefit of society through various means, such as startup company spinoffs, inclusion of Columbia technology as important product features and more.  One positive side-benefit of this includes revenue generation from intellectual property.  
+
'''Columbia Technology Ventures''' (formerly [http://www.techventures.columbia.edu '''Science and Technology Ventures'''], also known as '''Tech Ventures'''), is the technology transfer office of Columbia University. The office manages Columbia's inventions and intellectual property portfolio.  Columbia's technology transfer operation has consistently ranked in the top five of universities for the past decade (measured by annual licensing revenues).
  
−
Columbia University is recognized by industry as one of the best sources of adaptable innovation in the country, and consistently ranks in the top three by revenues on licenses year over year for the past decade.   
+
==Purpose==
 +
Columbia University is widely recognized and respected as a leading source of new scientific knowledge and innovation in the world.  Columbia faculty, students, and research staff transfer much of this knowledge and innovation outside of the university through public discourse and publications.  In certain situations, however, it may be appropriate to pursue protection of copyrights or patent rights for some of these new ideas and inventions, in order to provide market incentives to facilitate the transfer and development of new technologies, products, and services.   
  
−
[[Richard Axel]]'s patent is the richest patent in higher education history.
+
As a non-profit teaching and research institution, Columbia is not in the business of developing, manufacturing, and selling commercial products. Instead, through Columbia Technology Ventures, Columbia works with commercial partners to develop, adapt, and apply University technology for the benefit of society. Commonly, this is done by licensing technologies to industrial partners who wish to develop products or services based on those technologies.  Occasionally, it's more appropriate to create a spin-off to bring a technology to market.  Through its Venture Lab program, Columbia Technology Ventures provides advisory and other services and resources to faculty, staff, and students interested in start-ups and entrepreneurship. On average, the office triages more than 300 new invention disclosures, executes 50-60 license deals, and helps launch 10-12 start-ups each year.
  
−
[[Orin Herskowitz]] is Chief Operating Officer for Science and Technology Ventures. [http://stv.columbia.edu/index.php?option=com_content&task=view&id=49&Itemid=69]
+
==History==
 +
Columbia Technology Ventures, founded in [[1982]], has gone through several name changes over the years (formerly known as '''Science & Technology Ventures (STV)''', '''Columbia Innovation Enterprise (CIE)''', and '''Office of Science & Technology Development (OSTD)''').
 +
 
 +
===Successes, Past and Present===
 +
A side-benefit of technology transfer activity is the generation of revenues, which are shared between inventors and the University. Columbia has reinvested these proceeds into recruiting new faculty, building new research programs and departments, and upgrading and expanding campus facilities. According to the Association of University Technology Managers (AUTM [http://www.autm.net]) 2007 Survey, Columbia University received approximately $136M in annual licensing revenues.
 +
 
 +
Columbia’s inventions are behind several well-known biopharmaceutical products, including Remicade; ReoPro; Tysabri; Erbitux; Simponi; Zolinza; Synagis; Xalatan / Xalcom; Epogen; Avonex; and Herceptin, as well as consumer products, including the Apple iPhone/iTouch, DVDs, LCDs, VOIP, video-on-demand, and HDTV.
 +
 
 +
==Organization, Employment, and Student Participation==
 +
Columbia Technology Ventures reports into the Office of the [[Senior Executive Vice President]] (currently [[Robert Kasdin]]).  Orin Herskowitz is the current Executive Director of the office. 
 +
 
 +
The office is run by 45 full-time staff, including 10 [[PhD]]s, 9 [[JD]]s, and 6 [[Master of Business Administration|MBA]]s, at two offices, on Columbia’s [[Morningside Heights campus|Morningside]] and [[Medical Center]] campuses.  Columbia Technology Ventures also has a popular program for Columbia graduate students, called the Fellows Program.  Through the Fellows Program, students gain a solid introduction to and experience with technology transfer while supporting technology marketing activities, e.g. market research/diligence, business planning, technology marketing, etc.
  
 
== External links ==
 
== External links ==
−
* [http://www.stv.columbia.edu/ Science and Technology Ventures Site]
+
* [mailto:techventures@columbia.edu Contact Email Address]
−
* [http://media.www.columbiaspectator.com/media/storage/paper865/news/2006/11/28/News/Patents.Bring.In.The.Cash.To.Columbia-2509908.shtml Patents Bring in the Cash to Columbia] - [[Columbia Daily Spectator|The Spectator]] ''11-28-06''
+
* [http://www.techventures.columbia.edu/ Columbia Technology Ventures website]
 +
* [http://www.newswise.com/articles/columbia-university-licenses-pathogen-detection-technology-to-vimta-labs-platform-allows-for-rapid-identification-of-multiple-pathogens-in-single-test Columbia University Licenses Pathogen Detection Technology to Vimta Labs]
 +
*  [http://www.newswise.com/articles/endorobotics-and-columbia-university-announce-agreement-to-develop-robotic-imaging-and-surgical-device-for-minimally-invasive-surgery EndoRobotics and Columbia University Announce Agreement to Develop Robotic Imaging and Surgical Device for Minimally Invasive Surgery]
 +
* [http://www.newswise.com/articles/tocris-bioscience-first-to-launch-novel-light-sensitive-caged-gaba-compound-rubi-gaba-licensed-from-columbia-university Tocris Bioscience First to Launch Novel Light-Sensitive Caged GABA Compound: RuBi-GABA Licensed from Columbia University]
 +
* [http://www.newswise.com/articles/columbia-university-licenses-retinal-imaging-technology-to-pcasso-diagnostics Columbia University Licenses Retinal Imaging Technology to PCAsso Diagnostics]
 +
* [http://www.newswise.com/articles/columbia-university-licenses-in-vitro-fertilization-technology-to-vital-view Columbia University Licenses In Vitro Fertilization Technology to Vital View]
 +
* [http://www.newswise.com/articles/columbia-university-and-university-of-nebraska-license-targeted-anti-cancer-therapy-to-stockbridge-pharmaceuticals Columbia University and University of Nebraska License Targeted Anti-Cancer Therapy to Stockbridge Pharmaceuticals]
 +
* [http://www.newswise.com/articles/columbia-universitys-proven-natural-language-processing-technology-licensed-to-nlp-international Columbia University's Proven Natural Language Processing Technology Licensed to NLP International]
  
 
[[Category:University components]]
 
[[Category:University components]]

Latest revision as of 16:18, 24 May 2013

Columbia Technology Ventures (formerly Science and Technology Ventures, also known as Tech Ventures), is the technology transfer office of Columbia University. The office manages Columbia's inventions and intellectual property portfolio. Columbia's technology transfer operation has consistently ranked in the top five of universities for the past decade (measured by annual licensing revenues).

Purpose

Columbia University is widely recognized and respected as a leading source of new scientific knowledge and innovation in the world. Columbia faculty, students, and research staff transfer much of this knowledge and innovation outside of the university through public discourse and publications. In certain situations, however, it may be appropriate to pursue protection of copyrights or patent rights for some of these new ideas and inventions, in order to provide market incentives to facilitate the transfer and development of new technologies, products, and services.

As a non-profit teaching and research institution, Columbia is not in the business of developing, manufacturing, and selling commercial products. Instead, through Columbia Technology Ventures, Columbia works with commercial partners to develop, adapt, and apply University technology for the benefit of society. Commonly, this is done by licensing technologies to industrial partners who wish to develop products or services based on those technologies. Occasionally, it's more appropriate to create a spin-off to bring a technology to market. Through its Venture Lab program, Columbia Technology Ventures provides advisory and other services and resources to faculty, staff, and students interested in start-ups and entrepreneurship. On average, the office triages more than 300 new invention disclosures, executes 50-60 license deals, and helps launch 10-12 start-ups each year.

History

Columbia Technology Ventures, founded in 1982, has gone through several name changes over the years (formerly known as Science & Technology Ventures (STV), Columbia Innovation Enterprise (CIE), and Office of Science & Technology Development (OSTD)).

Successes, Past and Present

A side-benefit of technology transfer activity is the generation of revenues, which are shared between inventors and the University. Columbia has reinvested these proceeds into recruiting new faculty, building new research programs and departments, and upgrading and expanding campus facilities. According to the Association of University Technology Managers (AUTM [1]) 2007 Survey, Columbia University received approximately $136M in annual licensing revenues.

Columbia’s inventions are behind several well-known biopharmaceutical products, including Remicade; ReoPro; Tysabri; Erbitux; Simponi; Zolinza; Synagis; Xalatan / Xalcom; Epogen; Avonex; and Herceptin, as well as consumer products, including the Apple iPhone/iTouch, DVDs, LCDs, VOIP, video-on-demand, and HDTV.

Organization, Employment, and Student Participation

Columbia Technology Ventures reports into the Office of the Senior Executive Vice President (currently Robert Kasdin). Orin Herskowitz is the current Executive Director of the office.

The office is run by 45 full-time staff, including 10 PhDs, 9 JDs, and 6 MBAs, at two offices, on Columbia’s Morningside and Medical Center campuses. Columbia Technology Ventures also has a popular program for Columbia graduate students, called the Fellows Program. Through the Fellows Program, students gain a solid introduction to and experience with technology transfer while supporting technology marketing activities, e.g. market research/diligence, business planning, technology marketing, etc.

External links

Retrieved from "https://www.wikicu.com/index.php?title=Columbia_Technology_Ventures&oldid=46452"